AgomAb Therapeutics NV American Depositary Shares (AGMB)

About AGMB

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-44…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

62

Website

agomab.com/

Fundamentals

1-day range

$7.92$8.53

Market cap

$664.85M

P/E (trailing)

—

P/E (forward)

-4.04

EPS (trailing)

$-1.28

Dividend yield

—

Beta

1.60

Avg. volume

139.8K

Forecasts

6 analyst ratings

AgomAb Therapeutics NV American Depositary Shares Competitors

Chosen by industry and closest market cap.

• AGMB

  AgomAb Therapeutics NV American Depositary Shares

  $8.28

  ▼ 0.60%
  Market cap $664.85MP/E —
  $7.97$17.82
• ALLO

  Allogene Therapeutics Inc. Common Stock

  $1.31

  ▼ 2.24%
  Market cap $679.95MP/E —
  $1.04$4.46
• RGNX

  REGENXBIO Inc. Common Stock

  $6.93

  ▼ 3.28%
  Market cap $583.15MP/E —
  $5.46$16.19
• TECX

  Tectonic Therapeutic Inc. Common Stock

  $20.65

  ▼ 3.05%
  Market cap $570.23MP/E —
  $14.6$39.53
• ARTV

  Artiva Biotherapeutics Inc. Common Stock

  $5.85

  ▼ 3.47%
  Market cap $566.10MP/E —
  $2.75$14.53
• CADL

  Candel Therapeutics Inc. Common Stock

  $8.19

  ▼ 8.08%
  Market cap $775.20MP/E —
  $4.35$14
• FDMT

  4D Molecular Therapeutics Inc. Common Stock

  $12.14

  ▼ 5.67%
  Market cap $551.51MP/E —
  $6.96$16.93

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Agomab Therapeutics Doses First Patient In NOV-ERA, Global Phase 2b Study Evaluating Ontunisertib In Patients With Symptomatic FSCD
  benzinga · 10/13/2026
• Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
  Yahoo · 10/8/2026
• AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
  SeekingAlpha · 10/1/2026
• 12 Health Care Stocks Moving In Thursday's After-Market Session
  Benzinga · 10/1/2026
• Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
  Benzinga · 10/1/2026
• Agomab stock jumps on positive trial data
  Yahoo · 10/1/2026
• 12 Health Care Stocks Moving In Thursday's Intraday Session
  Benzinga · 10/1/2026
• Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
  Yahoo · 10/1/2026
• Agomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In Patients With Severe Crohn's Disease; Favorable Safety And Tolerability Profile Maintained Through Up To 60 Weeks Of Treatment; Low Annualized FSCD-Related Event Rate Of 3%
  Benzinga · 10/1/2026

• David R. Epstein · October 8, 2026 · Buy

  5.0K @ $8.9
• Knotnerus Tim Jasper · October 6, 2026 · Buy

  5.0K @ $8.7
• Kemula Pierre Thadee Victor · October 6, 2026 · Buy

  2.0K @ $8.54
• Kemula Pierre Thadee Victor · October 6, 2026 · Buy

  5.0K @ $8.57
• Kemula Pierre Thadee Victor · October 6, 2026 · Buy

  3.0K @ $8.67
• David R. Epstein · October 6, 2026 · Buy

  5.0K @ $8.7
• Knotnerus Tim Jasper · October 5, 2026 · Buy

  6.0K @ $8.48
• David R. Epstein · October 5, 2026 · Buy

  5.0K @ $8.57
• Naimish Patel · September 11, 2026 · Grant

  56.3K
• Marino Garcia · September 11, 2026 · Grant

  57.5K

Institutional Ownership

March 31, 2026

Total shares held

23.35M

Total value held

$245.05M

Institutional holders

32